Photopheresis in Early-stage Mycosis Fungoides

Photopheresis in Early-stage Mycosis Fungoides
Experimental: UVA Sterile Solution in conjunction with the UVAR® THERAKOS® CELLEX Photopheresis System

TREATMENT with THERAKOS® CELLEX Photopheresis System on two consecutive days every 2 weeks for the first 3 months; then once per month for following 9 months.

Drug: UVADEX® (methoxsalen) Sterile Solution in conjunction with the UVAR® THERAKOS® CELLEX Photopheresis

Extracorporeal Photopheresis (ECP)

Device: THERAKOS® CELLEX photopheresis system

UVAR® THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 12, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments